Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority review on a key drug and Third Harmonic restructured.

--Traded as low as $85.73; lowest intraday level since Sept. 27, 2022, when it hit $85.67 These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or ...

Merck Foundation Marks International Day of Girls & Women in Science 2025 by providing Over 1000 Scholarships to Women ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

In this piece, we will look at the stocks Jim Cramer recently discussed.

Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...